Tocagen Logo Green

No One Should Die of CancerTM

Our lead product candidate involves a cancer-selective virus and is in a clinical trial, Toca 5, for patients with brain cancer.

Tocagen believes cancer should be a manageable disease, and that long-term remission or elimination of the disease is possible. Driven by this vision, we are developing first-in-class, broadly applicable, cancer-selective gene therapies that are designed to activate a patient’s immune system against their own cancer from within.